Bağımlılığın Nörobiyolojisi ve Temel Psikofarmakolojik İlkeler
Özet
Alkol ve madde kullanım bozuklukları (AMKB), bireysel ve toplumsal etkileriyle öne çıkan kronik halk sağlığı sorunlarıdır. Bağımlılık yapıcı maddeler, beyindeki haz ve ödül yolaklarını doğrudan aktive ederek kişide tekrar kullanım motivasyonu oluşturur. Bu süreç zamanla dürtüsel kullanımdan kompulsif nitelikteki kronik bir yapıya evrilerek; aşırı kullanım, yoksunluk ve zihinsel uğraşı şeklinde üç farklı kronik dönem izler. Nöroanatomik olarak mezolimbik dopaminerjik ödül sistemi (VTA, NAC, PFC, amigdala ve hipokampus) bu mekanizmanın merkezinde yer almaktadır. Dopamin ana nörotransmitter olmakla birlikte; GABA, glutamat, serotonin, noradrenalin, adenozin, kolesistokinin ve nitrik oksit gibi nörokimyasallar da ödül arama, anksiyete ve yoksunluk semptomlarında kritik roller üstlenir. Genetik faktörler, epigenetik değişiklikler ve nöroplastisite bağımlılığın gelişmesinde ve sürdürülmesinde poligenik bir temel oluşturmaktadır. Son yarım asırda psikofarmakolojik tedavi seçeneklerinde önemli gelişmeler kaydedilmiş olup, hastanın durumuna göre arındırma ve nüksü önleyici uzun dönem idame tedavileri uygulanmaktadır. Kalıcı nöroadaptif değişiklikler nedeniyle nüks riskinin ömür boyu sürebileceği gerçeği, hekim ile hasta arasında işbirlikçi ve uyumlu bir terapotik ittifak kurulmasını zorunlu kılmaktadır.
Alcohol and substance use disorders (ASUD) are chronic public health problems prominent for their individual and social impacts. Addictive substances directly activate reward pathways in the brain, creating a motivation for repeated use. Over time, this process evolves from impulsive use into a compulsive chronic structure, following three distinct phases: binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation. Neuroanatomically, the mesolimbic dopaminergic reward system (VTA, NAC, PFC, amygdala, and hippocampus) lies at the center of this mechanism. Although dopamine is the primary neurotransmitter, neurochemicals such as GABA, glutamate, serotonin, noradrenaline, adenosine, cholecystokinin, and nitric oxide also play critical roles in reward-seeking, anxiety, and withdrawal symptoms. Genetic factors, epigenetic changes, and neuroplasticity establish a polygenic foundation for the development and maintenance of addiction. Significant progress has been made in psychopharmacological treatment options over the last half-century, applying detoxification and long-term maintenance therapies depending on the patient's condition. The fact that the risk of relapse can last a lifetime due to permanent neuroadaptive changes necessitates the establishment of a collaborative and harmonious therapeutic alliance between the physician and the patient.
Referanslar
Uzbay İT. Madde bağımlılığı: Tüm boyutlarıyla bağımlılık ve bağımlılık yapan maddeler: İstanbul Tıp Kitabevi; 2015.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry. 2016;3(8):760-73.
UZBAY İT. Madde Bağimliliğinin Tarihçesi, Tanimi, Genel Bilgiler Ve Bağimlilik Yapan Maddeler. Meslek İçi Sürekli Eğitim Dergisi. 2009:5-15.
Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. American journal of psychiatry. 2001;158(11):1783-93.
Berlin GS, Hollander E. Compulsivity, impulsivity, and the DSM-5 process. CNS spectrums. 2014;19(1):62-8.
Nestler EJ. Is there a common molecular pathway for addiction? Nature neuroscience. 2005;8(11):1445-9.
Turton S, Lingford-Hughes A. Neurobiology and principles of addiction and tolerance. Medicine. 2016;44(12):693-6.
MacNicol B. The biology of addiction. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2017;64(2):141-8.
Kovacs KJ. Microglia and drug-induced plasticity in reward-related neuronal circuits. Frontiers in molecular neuroscience. 2012;5:74.
Uzbay İ. Madde bağımlılığı ve dopaminerjik sistem. Turkiye Klinikleri Journal of Internal Medical Sciences. 2005;1(47):65-72.
Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neuroscience & biobehavioral reviews. 2006;30(2):215-38.
Uzbayº H, Akarsu E, Kayaalpº S. Effects of flumazenil on ethanol withdrawal syndrome in rats. 1995.
O’Brien CP. Drug addiction and drug abuse. Brunton LL, Lazo JS & Parker KL, Goodman & Gilman's 11th Ed The Pharmacological Basis of Therapeutics. 2006:607-28.
Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. The American journal of psychiatry. 1995.
Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251(4989):85-7.
Uzbay I, Usanmaz S, Tapanyigit E, Aynacioglu S, Akarsu E. Dopaminergic and serotonergic alterations in the rat brain during ethanol withdrawal: association with behavioral signs. Drug and alcohol dependence. 1998;53(1):39-47.
Uzbay I, Usanmaz S, Akarsu E. Effects of chronic ethanol administration on serotonin metabolism in the various regions of the rat brain. Neurochemical research. 2000;25(2):257-62.
Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. Anxiolytic activity of adenosine receptor activation in mice. British journal of pharmacology. 1995;116(3):2127.
Wilson J, Little H. CCKB antagonists protect against some aspects of the ethanol withdrawal syndrome. Pharmacology Biochemistry and Behavior. 1998;59(4):967-73.
Uzbay IT, Oglesby MW. Nitric oxide and substance dependence. Neuroscience & Biobehavioral Reviews. 2001;25(1):43-52.
Uzbay TI. The pharmacological importance of agmatine in the brain. Neuroscience & Biobehavioral Reviews. 2012;36(1):502-19.
Yeşilyurt Ö, Uzbay IT. Agmatine potentiates the analgesic effect of morphine by an α2-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology. 2001;25(1):98-103.
Aricioglu-Kartal F, Uzbay IT. Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life sciences. 1997;61(18):1775-81.
Uzbay T, Kayir H, Goktalay G, Yildirim M. Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. Journal of Psychopharmacology. 2010;24(6):923-9.
Uzbay T, Goktalay G, Kayir H, Eker SS, Sarandol A, Oral S, et al. Increased plasma agmatine levels in patients with schizophrenia. Journal of psychiatric research. 2013;47(8):1054-60.
Morrow JD, Flagel SB. Neuroscience of resilience and vulnerability for addiction medicine: from genes to behavior. Progress in brain research. 2016;223:3-18.
Hurley TD, Edenberg HJ. Genes encoding enzymes involved in ethanol metabolism. Alcohol research: current reviews. 2012;34(3):339.
Wang J-C, Kapoor M, Goate AM. The genetics of substance dependence. Annual review of genomics and human genetics. 2012;13:241.
Hall FS, Drgonova J, Jain S, Uhl GR. Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacology & therapeutics. 2013;140(3):267-79.
Renthal W, Nestler EJ. Epigenetic mechanisms in drug addiction. Trends in molecular medicine. 2008;14(8):341-50.
Uzbay T, Öz P, Gözaydınoğlu Ş. Genoplasticity and neuropsychiatric diseases. Pharmacology. 2019;23.
Nestler EJ, Lüscher C. The molecular basis of drug addiction: linking epigenetic to synaptic and circuit mechanisms. Neuron. 2019;102(1):48-59.
Bowirrat A, Oscar‐Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2005;132(1):29-37.
Blum K, Noble EP, Sheridan PJ, Finley O, Montgomery A, Ritchie T, et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol. 1991;8(5):409-16.
Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2003;116(1):103-25.
Gelernter J, O'Malley S, Risch N, Kranzler HR, Krystal J, Merikangas K, et al. No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. Jama. 1991;266(13):1801-7.
Edenberg HJ, Foroud T, Koller DL, Goate A, Rice J, Van Eerdewegh P, et al. A family‐based analysis of the association of the dopamine D2 receptor (DRD2) with alcoholism. Alcoholism: Clinical and Experimental Research. 1998;22(2):505-12.
Rutherford HJ, Williams SK, Moy S, Mayes LC, Johns JM. Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems. Frontiers in psychiatry. 2011;2:37.
Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. European Neuropsychopharmacology. 2007;17(6-7):377-93.
Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ, et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14(2):169-77.
Volkow ND, Chang L, Wang G-J, Fowler JS, Ding Y-S, Sedler M, et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. American Journal of Psychiatry. 2001;158(12):2015-21.
López-Muñoz F, Alamo C, Rubio G, Cuenca E. Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):205-8.
